THE PROBLEM
.png)
Autoimmune diseases persist due to fragmented data, late
diagnostics, and slow regulations.
ASDF unites this landscape,
harnessing advanced technology and regulatory expertise to deliver
early diagnoses and life-changing cures.
We're going to cure autoimmune diseases—permanently.
OUR MISSION
We invest in health & bio-tech companies, diagnostic tools, and valuable data sources that help permanently cure autoimmune diseases.
Each investment is chosen carefully, deal-by-deal, to make sure it
clearly improves people’s health and provides strong financial
returns to our investors.
OUR VISION
A world where autoimmune diseases are found and treated
quickly—long before they cause lasting harm.
We imagine a
future where technology, data, and smart investment come
together to cure diseases that millions of people currently suffer
from.
OUR VALUES
Impact First
We only invest in projects that
clearly improve lives, health,
and the environment.
.png)
Visionary Collaboration
We team up with people brave
enough to tackle the world’s
biggest health challenges.
.png)
Radical Transparency
Investors always know exactly
where their money goes and
how it helps.
.png)
Sustainable Prosperity
We know meaningful change
and financial success work best
together. Making an impact
also makes good business
sense.
GOALS
01
Launch and establish GP by raising an initial $20M in founding capital.
02
Deploy $40M into health startups and core assets within 12 months.
03
Scale investments by 10x within 3 years, expanding strongly into autoimmune healthcare, diagnostics, and advanced technology.
04
Achieve $1B+ AUM by year 5, establishing leadership in autoimmune cures and tech-enabled diagnostics.
STRATEGY
Centralized Data - Acquire and unify autoimmune data into a proprietary asset.
Predictive diagnostics - Invest directly in diagnostic tools powered by predictive AI.
Regulatory speed - leverage deep relationships and internal expertise to accelerated FDA pathways.
Balanced portfolio - close collaboration with visionary teams, adding strategic value beyond
capital.
RESEARCH
Deep Market Insights: We carefully track autoimmune technology and healthcare markets, finding the best opportunities early.
Careful Evaluation: We use our FDA experience to carefully check investments for regulatory risks.
Expert Network: We leverage relationships with industry experts, scientists, and entrepreneurs for
specialized insights.
Impact-Focused Diligence: We prioritize companies whose solutions clearly benefit health, environment, and society.
ANALYSIS
We focus on leadership teams with proven wins (and insightful losses), clear paths to profit, and bold visions for the future.
We seek the spark that turns smart ideas into exceptional investments.
EDGE
We're transparent about our strengths—and partner strategically to address our gaps.
Tech Expertise
Proven leader from Tesla, SpaceX, Nike.
.png)
Direct FDA advantage
accelerated approval paths
Proprietary data assets
Proprietary autoimmune data assets = unique insights
.png)
Empathetic Leadership
Driven by personal resilience (Type 1 Diabetes).
ASK: $20M GP RAISE
Purpose: Build out fund infrastructure and deploy initial capital.
Minimum GP Check: $400K.
We're actively seeking experienced partners:
Core GPs
-
Experienced Fund Managers (VC, PE, SPV)
-
Recently Exited Entrepreneurs (strong networks & credibility)
-
Finance Experts (CFO, CPA, Investment Banker)
GP/Advisor
-
Medical/Biotech Experts (autoimmune & healthcare domain)
SUBSCRIBE TO OUR NEWSLETTER
Advisors & Board Candidates
We're engaging world-class executives and scientific leaders to guide our strategic direction and accelerate our impact.
LEE SIMON, MD, FACP, MACR
Former FDA Division Director
Analgesic, Anti-inflammatory, Ophthalmologic Drug Products Division
(Immunology, Clinical Trials & FDA Regulatory Strategy Advisor)
-
Renowned expert in autoimmune clinical trials and FDA regulatory strategy.
-
Decades of experience leading successful clinical development, regulatory pathways, and biotech innovations.
-
Provides strategic insights to ensure successful investment decisions and regulatory alignment.
Rob Scott, MD (Candidate)
Former Chief Medical Officer, AbbVie
(Immunology, FDA Regulatory Strategy)
Confidential Candidate
Former President at a Leading Global Healthcare Firm
Confidential Candidate
CEO in Pioneering Biotech (ex-Google executive)
Confidential Candidate
Senior Executives from Roche, Eli Lilly, Pfizer, Celgene
Confidential Candidate
Renowned Immunologist & Biotech CEO (Top-5 Pharma)
.png)